Novartis (NVS) Projected to Post Earnings on Tuesday

Novartis (NYSE:NVS) is expected to be issuing its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect the company to announce earnings of $2.13 per share and revenue of $13.5421 billion for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:00 AM ET.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.99 by $0.04. Novartis had a return on equity of 40.53% and a net margin of 25.65%.The company had revenue of $13.86 billion for the quarter, compared to analysts’ expectations of $13.85 billion. During the same period last year, the firm posted $1.98 earnings per share. Novartis’s revenue was up 1.4% compared to the same quarter last year. On average, analysts expect Novartis to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Novartis Price Performance

Shares of NYSE:NVS opened at $150.96 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.89 and a current ratio of 1.12. The firm has a market cap of $288.05 billion, a price-to-earnings ratio of 21.08, a price-to-earnings-growth ratio of 2.60 and a beta of 0.52. The business has a 50-day simple moving average of $156.93 and a two-hundred day simple moving average of $143.13. Novartis has a fifty-two week low of $104.93 and a fifty-two week high of $170.46.

Novartis Announces Dividend

The company also recently declared an annual dividend, which was paid on Monday, March 16th. Stockholders of record on Wednesday, March 11th were issued a dividend of $4.773 per share. This represents a dividend yield of 306.0%. The ex-dividend date of this dividend was Wednesday, March 11th. Novartis’s dividend payout ratio is presently 43.02%.

Institutional Trading of Novartis

Several hedge funds and other institutional investors have recently made changes to their positions in NVS. CrossGen Wealth LLC acquired a new stake in shares of Novartis in the 4th quarter worth $28,000. Bank of Jackson Hole Trust increased its position in Novartis by 425.0% during the 4th quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock valued at $32,000 after buying an additional 187 shares in the last quarter. Measured Wealth Private Client Group LLC purchased a new stake in Novartis in the third quarter valued at about $33,000. Pin Oak Investment Advisors Inc. raised its stake in Novartis by 25.2% in the third quarter. Pin Oak Investment Advisors Inc. now owns 462 shares of the company’s stock valued at $59,000 after buying an additional 93 shares during the last quarter. Finally, Litman Gregory Wealth Management LLC acquired a new stake in Novartis in the fourth quarter worth about $65,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on NVS. Citigroup reaffirmed a “buy” rating on shares of Novartis in a report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a research note on Thursday, February 12th. Sanford C. Bernstein upgraded shares of Novartis to a “hold” rating in a research report on Thursday, March 19th. Barclays raised shares of Novartis from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Finally, Wall Street Zen downgraded Novartis from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $141.20.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.